Eszopiclone is a sedative-hypnotic used in the treatment of insomnia, improving both the latency phase and the maintenance phase of sleep. Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia.
- Mechanism
- Curator reviewed · 7 references
The exact mechanism of action of eszopiclone is unknown at this time but is thought to occur via binding with the GABA receptor complexes at binding sites located near benzodiazepine receptors, possibly explaining its hypnotic and sedative effects. It has particular affinity for GABA-A (or GABAA) receptor subunits 1, 3 and 5. Eszopiclone increases GABA-A channel currents significantly. GABA-A channels are major inhibitory channels that cause CNS depression when their receptors are activated.
- Primary indication
- Eszopiclone is indicated for the treatment of insomnia.Curator reviewed · 1 structured indication
- Formula / weight
- C17H17ClN6O3 · 388.808 g/mol (avg)
- First approval
- Canada, 2024 · United States, 2005
- Also known as
- (S)-Zopiclone · Esopiclone
- Code names
- GSK-1755165
- Brand names
Resolves to
GBBSUAFBMRNDJC-INIZCTEOSA-NSMILESCN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1What you can answer from here — as of September 20, 2026
Which drugs share a target with Eszopiclone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account